Sign in

    Shrunatra Mishra

    Research Analyst at Goldman Sachs

    Shrunatra Mishra is an Associate at Goldman Sachs & Co. LLC, specializing in equity research with a focus on the pharmaceuticals sector. Mishra has covered companies such as Apellis Pharmaceuticals Inc., actively participating in earnings calls and providing analysis on key clinical data outcomes and competitive dynamics. Since joining Goldman Sachs in 2022, Mishra has accumulated over two years of professional experience in the industry, and has previously worked as an Equity Research Analyst at the same firm. Professionally credentialed and regulated by FINRA (CRD#: 7566219), Mishra holds the requisite securities licenses to act as a broker and research analyst at Goldman Sachs.

    Shrunatra Mishra's questions to Apellis Pharmaceuticals (APLS) leadership

    Shrunatra Mishra's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Shrunatra Mishra, on behalf of Salveen Richter at Goldman Sachs, asked if the guidance for low to mid-single-digit quarterly injection growth for Cyfovri is conservative and when an acceleration in this growth rate might be expected.

    Answer

    Co-Founder and CEO Dr. Cedric Francois characterized the Cyfovri business as stable with steady, gradual growth. He emphasized that with only about 10% of the patient population treated, there is a long runway for growth through continued education of the retina community.

    Ask Fintool Equity Research AI

    Shrunatra Mishra's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Shrunatra Mishra, on behalf of Salveen Richter at Goldman Sachs, asked if the company's expectation for low to mid-single-digit quarterly injection growth for Cyfovri is a conservative estimate and when an acceleration in this growth rate might occur.

    Answer

    CEO Dr. Cedric Francois characterized the Cyfovri business as having achieved stability with steady and gradual growth. He emphasized that with only a little over 10% of the GA market treated, this stability allows Apellis to focus on educating the retina community and capturing the significant long-term opportunity.

    Ask Fintool Equity Research AI

    Shrunatra Mishra's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Shrunatra Mishra, on behalf of Goldman Sachs, asked if the Q-o-Q injection growth expectation of low to mid-single digits for Cyfovri is a conservative estimate and when an acceleration in this growth rate might be expected.

    Answer

    Co-Founder and CEO Cedric Francois characterized the Cyfovri business as stable with steady, gradual growth. He emphasized that this stability allows the company to focus on educating the retina community and penetrating the large, undertreated patient population, noting that only a little over 10% of GA patients have been treated so far.

    Ask Fintool Equity Research AI

    Shrunatra Mishra's questions to Apellis Pharmaceuticals (APLS) leadership • Q2 2025

    Question

    Shrunatra Mishra, on behalf of Salveen Richter at Goldman Sachs, asked if the guidance for low to mid-single-digit quarterly injection growth for Cyfovri is conservative and when an acceleration in this growth rate might be expected.

    Answer

    CEO Dr. Cedric Francois described the Cyfovri business as having achieved a stable state with steady, gradual growth. He emphasized that with only about 10% of the GA market treated, this stability provides a strong foundation to continue educating the retina community and capturing the significant long-term opportunity.

    Ask Fintool Equity Research AI

    Shrunatra Mishra's questions to Sage Therapeutics (SAGE) leadership

    Shrunatra Mishra's questions to Sage Therapeutics (SAGE) leadership • Q1 2025

    Question

    Shrunatra Mishra of Leerink Partners inquired about Sage's pipeline, upcoming catalysts, and the company's confidence in the GABA and NMDA pathways following previous setbacks.

    Answer

    CEO Barry Greene and CSO Mike Quirk explained that Sage has recalibrated its R&D approach to focus on neuropsychiatry and neurodevelopmental disorders with strong biological rationale. They highlighted SAGE-319 and the NMDA NAM platform, which leverage clinical insights from validated targets like ketamine but aim for an improved tolerability profile. The strategy prioritizes indications with feasible regulatory pathways and a clear potential for value creation.

    Ask Fintool Equity Research AI

    Shrunatra Mishra's questions to Sage Therapeutics (SAGE) leadership • Q3 2024

    Question

    Shrunatra Mishra, on for Salveen Richter, asked about the early-stage pipeline, specifically data timelines for SAGE-319, and any optimization in the Zurzuvae specialty pharma fulfillment process.

    Answer

    CEO Barry Greene confirmed the specialty pharma process for Zurzuvae is improving quarterly with few complaints. Chief Medical Officer Laura Gault added that SAGE-319, an extra-synaptic preferring GABA PAM, is in Phase I, and its different pharmacological profile is expected to translate to a differentiated clinical profile.

    Ask Fintool Equity Research AI